Sickle cell drug hits fast track
August 1, 1999 less than 1 minute read
Sickle cell drug hits fast track
A purified poloxamer intravenous drug in Phase III trials as Flocor by CytRx Corp. in Atlanta has been granted fast-track status by the Food and Drug Administration for its success in clinical trials at alleviating the vaso-occlusive acute pain associated with sickle cell anemia.
The drug won’t cure the genetically inherited disease, but it is being hailed as a potential step in that direction for its ability to counter the disease-causing breakdown of hemoglobin in red blood cells, which causes the cells to become rigid and inflexible, which in turn impedes blood flow and causes acute pain.
CytRx expects to file a New Drug Application for Flocor by the end of this year.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content